Lunaphore Technologies SA, a Swiss life-sciences company, developing innovative next-generation equipment for cancer research and tissue diagnostics, announces the first closing of its Series C funding, amounting to CHF 23 million (approx €21 million).
The round was led by the Japanese strategic investor PHC Holdings Corporation, a global healthcare company that owns Epredia. Existing investors, including Redalpine Venture Partners, OCCIDENT, and Alpana Ventures, have also participated in this financing round.